Drug-induced erectile dysfunction
Methodology & AI Transparency ⓘ
Drug-induced erectile dysfunction Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Drug-induced erectile dysfunction (N52.2; Men's Health, Testosterone & Sexual Function) utilize cardiometabolic workup [Drug-induced erectile dysfunction N52.2] and objective Morning Total & in Drug-induced erectile dysfunction (N52.2: Free Testosterone (2x) targets (Total 500–900 ng/dL; Free 110–210 pg/mL (N52.2)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Federal ICD-10-CM code N52.2 categorizes Drug-induced erectile dysfunction under Men's Health, Testosterone & Sexual Function.
- 3 Typical cash cost range: Primary evaluation for Drug-induced erectile dysfunction incorporates cardiometabolic workup [Drug-induced erectile dysfunction N52.2] and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Drug-induced erectile dysfunction: Morning Total & in Drug-induced erectile dysfunction (N52.2: Free Testosterone (2x) (Total 500–900 ng/dL; Free 110–210 pg/mL (N52.2)) and LH, FSH & in Drug-induced erectile dysfunction (N52.2: SHBG).
Ask our AI Specialists anything about Drug-induced erectile dysfunction
What Is Drug-induced erectile dysfunction?
Physicians managing Drug-induced erectile dysfunction (N52.2; Men's Health, Testosterone & Sexual Function) utilize cardiometabolic workup [Drug-induced erectile dysfunction N52.2] and objective Morning Total & in Drug-induced erectile dysfunction (N52.2: Free Testosterone (2x) targets (Total 500–900 ng/dL; Free 110–210 pg/mL (N52.2)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in men's health & trt, Drug-induced erectile dysfunction (N52.2) involves primary testicular Leydig in Drug-induced erectile dysfunction (N52.2: cell insufficiency or). progression correlates with shifts in Morning Total & in Drug-induced erectile dysfunction (N52.2: Free Testosterone (2x) (Total 500–900 ng/dL; Free 110–210 pg/mL (N52.2)).
Common Symptoms & Clinical Signs
- • Presentation of Drug-induced erectile dysfunction (N52.2): two consecutive morning in Drug-induced erectile dysfunction (N52.2: total testosterone readings)
- • Secondary Drug-induced erectile dysfunction clinical sign: reduced sexual desire, in Drug-induced erectile dysfunction (N52.2: fewer spontaneous morning)
- • Symptom flares in Drug-induced erectile dysfunction correlating with Morning Total & in Drug-induced erectile dysfunction (N52.2: Free Testosterone (2x) deviation outside Total 500–900 ng/dL; Free 110–210 pg/mL (N52.2)
- • Functional men's health & trt impact requiring cardiometabolic workup [Drug-induced erectile dysfunction N52.2] evaluation (N52.2)
Drug-induced erectile dysfunction Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N52.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Men's Health, Testosterone & Sexual Function | NLM Clinical Tables |
| Diagnostic / Lab Marker: Morning Total & in Drug-induced erectile dysfunction (N52.2: Free Testosterone (2x) | Total 500–900 ng/dL; Free 110–210 pg/mL (N52.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: LH, FSH & in Drug-induced erectile dysfunction (N52.2: SHBG) | LH/FSH 2.5 – 8.0 mIU/mL (N52.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Hematocrit & Total in Drug-induced erectile dysfunction (N52.2: PSA) | Hct < 50%; age-appropriate PSA (N52.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Drug-induced erectile dysfunction
Treatment selection for Drug-induced erectile dysfunction depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Drug-induced erectile dysfunction)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy and tolerability of antidepressant drugs in treatment of depression in: What a 6,949-Participant Study Found A total of 33 RCTs were included in 32 articles, involving 6949 patients. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences • 2022-08-01 • Meta-Analysis | N = 6,949 | 99/100 | PMID 37202104 ↗ |
| New Insights on Is metformin still the most efficacious first-line oral hypoglycaemic drug in: What a 33,830-Participant Study Found This meta-analysis showed that repaglinide and metformin would be the most efficacious oral drugs for first-line single-drug treatment of T2DM. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2019-01-15 • Meta-Analysis | N = 33,830 | 99/100 | PMID 30230172 ↗ |
| New Insights on Long-Term heart and blood vessel Safety of Testosterone-Replacement Therapy in: What a 9,280-Participant Study Found In men with low to low-normal testosterone, aged 40 and above, TRT did not increase all-cause mortality, heart and blood vessel mortality, stroke, or heart attack, but increased the incidence of cardiac arrhythmias. American journal of cardiovascular drugs : drugs, devices, and other interventions • 2025-11-15 • Meta-Analysis | N = 9,280 | 99/100 | PMID 40694252 ↗ |
| New Insights on Benefits and safety of anti-prediabetic drugs in patients with prediabetes: a: What a 16,610-Participant Study Found Among all the included interventions, GLP-1RAs, GIP/GLP-1RAs, and TZDs demonstrated favorable anti-prediabetic efficacy and acceptable safety. BMC medicine • 2026-02-19 • Meta-Analysis | N = 16,610 | 99/100 | PMID 41715123 ↗ |
| New Insights on Comparative efficacy and acceptability of anxiolytic drugs for the treatment of: What a 28,637-Participant Study Found This network meta-analysis provides a unique comparison of the efficacy and acceptability of anxiolytics. European archives of psychiatry and clinical neuroscience • 2026-06-15 • Meta-Analysis | N = 28,637 | 99/100 | PMID 40788541 ↗ |
Drug-induced erectile dysfunction Patient Community & “People Like Me” Threads
Filter Drug-induced erectile dysfunction community threads and patient logs by age, biological sex, dosage, and treatment duration.